Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Rotavirus vaccine (RotaTeq).

Gillian M Keating1

  • 1Adis International Inc., Yardley, PA 19067, USA. demail@adis.com

Paediatric Drugs
|June 16, 2006
PubMed
Summary

RotaTeq, a rotavirus vaccine, effectively prevents G1-G4 rotavirus gastroenteritis in infants. This vaccine demonstrated high efficacy and safety, reducing healthcare utilization without increasing intussusception risk.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Correction to: Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2019
Same author

Afatinib in advanced NSCLC: a profile of its use.

Drugs & therapy perspectives : for rational drug selection and use·2018
Same author

Ticagrelor: A Review in Long Term Secondary Prevention of Cardiovascular Events.

Drugs·2017
Same author

Eluxadoline: A Review in Diarrhoea-Predominant Irritable Bowel Syndrome.

Drugs·2017
Same author

Sorafenib: A Review in Hepatocellular Carcinoma.

Targeted oncology·2017
Same author

Delta-9-Tetrahydrocannabinol/Cannabidiol Oromucosal Spray (Sativex<sup>®</sup>): A Review in Multiple Sclerosis-Related Spasticity.

Drugs·2017

Area of Science:

  • Pediatrics
  • Vaccinology
  • Gastroenterology

Background:

  • Rotavirus gastroenteritis poses a significant health risk to infants and children globally.
  • Development of effective vaccines is crucial for preventing rotavirus infections.

Purpose of the Study:

  • To evaluate the efficacy and safety of RotaTeq, a pentavalent rotavirus vaccine, in infants.
  • To assess the impact of RotaTeq on healthcare resource utilization.

Main Methods:

  • A randomized, double-blind, placebo-controlled, multicenter trial (REST study) involving over 4500 infants for efficacy and over 70,000 infants for safety analyses.
  • Administration of three oral doses of RotaTeq or placebo.

Main Results:

  • RotaTeq demonstrated 74% efficacy against any-severity G1-G4 rotavirus gastroenteritis and 98% efficacy against severe cases.
  • A 94.5% reduction in healthcare resource use for rotavirus gastroenteritis was observed.
  • No increased risk of intussusception was associated with RotaTeq, with serious adverse events occurring in <3% of infants in both vaccine and placebo groups.

Conclusions:

  • RotaTeq is an effective and safe vaccine for preventing G1-G4 rotavirus gastroenteritis in infants.
  • The vaccine significantly reduces the burden of rotavirus disease and associated healthcare costs.

Related Experiment Videos